TY - JOUR
T1 - Emotional expression during attention-deficit/hyperactivity disorders treatment
T2 - Initial assessment of treatment effects
AU - Kratochvil, Chris J.
AU - Faries, D.
AU - Vaughan, B.
AU - Perwien, A.
AU - Busner, J.
AU - Saylor, K.
AU - Kaplan, S.
AU - Buermeyer, C.
AU - Swindle, R.
PY - 2007/2/1
Y1 - 2007/2/1
N2 - Objective: The purpose of this research was to provide an initial examination of the effects of atomoxetine and stimulants on emotional expression using a newly developed scale for assessing emotional expression in children with attention-deficit/hyperactivily disorder (ADHD). Method: The parent-rated Expression and Emotion Scale for Children (EESC) was collected during two studies. During a cross-sectional validation study, the EESC was completed to assess the child's current treatment and retrospectively for previous medication. In a randomized, placebo-controlled trial of atomoxetine, the EESC was collected at baseline and endpoint. Results: In the validation study, no statistically significant differences in EESC scores were found between groups taking atomoxetine (n = 74) and stimulants (n = 105). Patients who switched from a stimulant to atomoxetine (n = 40) had greater improvement in emotional expression than those switched to another stimulant (n = 21) (p = 0.008). In the clinical trial, no difference in rates of worsening of emotional expression were observed (atomoxetine 8.3%, placebo 12.3%; p = 0.440). Conclusion: No treatment differences in emotional expression were observed based on current medications. However, stimulant patients needing to switch medications may have greater improvements in emotional expression by switching to atomoxetine.
AB - Objective: The purpose of this research was to provide an initial examination of the effects of atomoxetine and stimulants on emotional expression using a newly developed scale for assessing emotional expression in children with attention-deficit/hyperactivily disorder (ADHD). Method: The parent-rated Expression and Emotion Scale for Children (EESC) was collected during two studies. During a cross-sectional validation study, the EESC was completed to assess the child's current treatment and retrospectively for previous medication. In a randomized, placebo-controlled trial of atomoxetine, the EESC was collected at baseline and endpoint. Results: In the validation study, no statistically significant differences in EESC scores were found between groups taking atomoxetine (n = 74) and stimulants (n = 105). Patients who switched from a stimulant to atomoxetine (n = 40) had greater improvement in emotional expression than those switched to another stimulant (n = 21) (p = 0.008). In the clinical trial, no difference in rates of worsening of emotional expression were observed (atomoxetine 8.3%, placebo 12.3%; p = 0.440). Conclusion: No treatment differences in emotional expression were observed based on current medications. However, stimulant patients needing to switch medications may have greater improvements in emotional expression by switching to atomoxetine.
UR - http://www.scopus.com/inward/record.url?scp=33947412374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947412374&partnerID=8YFLogxK
U2 - 10.1089/cap.2006.0018
DO - 10.1089/cap.2006.0018
M3 - Article
C2 - 17343553
AN - SCOPUS:33947412374
SN - 1044-5463
VL - 17
SP - 51
EP - 62
JO - Journal of Child and Adolescent Psychopharmacology
JF - Journal of Child and Adolescent Psychopharmacology
IS - 1
ER -